Background and purpose Negative psychological outcomes occur frequently after stroke; however, there is uncertainty regarding the occurrence of anxiety disorders and anxiety symptoms after stroke. A systematic review of observational studies was conducted that assessed the frequency of anxiety in stroke patients using a diagnostic or screening tool. Summary of review Databases were searched up to March 2011. A random effects model was used to summarize the pooled estimate. Statistical heterogeneity was assessed using the I 2 statistic. Forty-four published studies comprising 5760 stroke patients were included. The overall pooled estimate of anxiety disorders assessed by clinical interview was 18% (95%confidence interval 8-29%, I 2 = 97%) and was 25% (95% confidence interval 21-28%, I 2 = 90%) for anxiety assessed by rating scale. The Hospital Anxiety and Depression Scale-Anxiety subscale 'probable' and 'possible' cutoff scores were the most widely used assessment criteria. The combined rate of anxiety by time after stroke was: 20% (95% confidence interval 13-27%, I 2 = 96%) within onemonth of stroke; 23% (95% confidence interval 19-27%, I 2 = 84%) one to five-months after stroke; and 24% (95% confidence interval 19-29%, I 2 = 89%) six-months or more after stroke. Conclusion Anxiety after stroke occurs frequently although methodological limitations in the primary studies may limit generalizability. Given the association between prevalence rates and the Hospital Anxiety and Depression Scale-Anxiety cutoff used in studies, reported rates could in fact underrepresent the extent of the problem. Additionally, risk factors for anxiety, its impact on patient outcomes, and effects in tangent with depression remain unclear.
Introduction
Globally, anxiety disorders are the most common mental health problem (1) . In some instances, anxiety is functionally appropriate and even advantageous when it prompts protective health behavior, and a certain amount would be considered a normal reaction to experiencing a life-threatening event such as stroke. However, anxiety disorders or anxiety 'caseness' (i.e. substantially elevated levels of anxiety symptoms as identified by a rating scale) are associated with reduced quality of life (2) , lead to increased healthcare utilization, and risk of disabling health conditions (3, 4) , and may even augment risk of death (5) .
The Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (6) classifies anxiety disorders as a collection of individual syndromes that include generalized anxiety disorder (GAD), panic disorder (with or without agoraphobia), agoraphobia (with or without panic), specific phobia, social phobia, obsessive compulsive disorder (OCD), posttraumatic stress disorder (PTSD), acute stress disorder, anxiety disorder due to a general medical condition, substance induced anxiety disorder, and anxiety disorder not otherwise specified. Each disorder has certain distinct features, yet they all share similar hallmark characteristics of excessive and irrational fear, feeling apprehensive and tense, and difficulty and distress in managing daily tasks. Certain physiological symptoms such as palpitations, dizziness, or trembling may also be present.
Anxiety has received substantially less attention relative to other psychological problems that occur poststroke (7) (8) (9) . Several reasons attribute to its neglect. Early population-based prevalence studies found that the frequency of anxiety disorders after stoke was low (10) . This would seem to be in keeping with epidemiologic studies in the general adult population that suggest that anxiety disorders are uncommon among older adults, and approximately three quarters of stroke patients are over 65 years of age (11) . However, one of the diagnostic challenges for assessing mood in stroke patients is that some symptoms of disorder, such as sleep disturbance or fatigue, are common consequences of stroke itself. This may have the effect of falsely reducing reported rates of mood disorder when using DSM criteria (12) .
As a result of these diagnostic challenges, the study of anxiety symptoms assessed by rating scale and not meeting full DSM criteria has proved extremely relevant. Studies have shown that people with subthreshold symptoms and diagnosed anxiety disorders are similarly affected by the anxiety (12) . Many stroke patients report substantial fears (possibly indicative of phobic disorders) about recurrent stroke, falling, or returning to work (13) (14) (15) ) that would be unlikely to constitute diagnosis of an anxiety or related mental health disorder, yet appear to impact significantly on daily living.
Additionally, comorbidity of anxiety and depression is well documented (16) . Traditional diagnostic and treatment approaches have used a hierarchical approach with depressive symptoms taking precedence. Furthermore, some argue that certain forms of anxiety should be conceptualized as a residual or severity marker of depression (17) . However, factor analysis has found that anxiety and depression appear to be distinct (16, 18, 19) , and differential response to treatment between the two conditions has been observed (20) .
The extent to which anxiety is a problem after stroke is uncertain. The aim of this review was to estimate the frequency of anxiety disorders after stroke. The frequency of anxiety 'caseness' as determined by a score on anxiety rating scales was also of interest. A robust estimate of poststroke anxiety prevalence is needed to assess its potential impact and highlight treatment needs.
Methods

Inclusion/exclusion criteria
The review included studies in populations or groups of patients who had a clinical diagnosis of ischemic or hemorrhagic stroke or transient ischemic attack (TIA) and were diagnosed with an anxiety disorder, or assessed for anxiety symptoms on a rating scale such as the Hospital Anxiety and Depression Scale (HADS). Non-English language papers that were potentially eligible based on their title or abstract were translated. Studies were excluded if they:
• were intervention studies; • were limited to patients with subarachnoid hemorrhage or other select characteristic such as gender;
• used nonspecific measures of psychological distress but not designed to screen expressly for an anxiety;
• involved retrospective recruitment or reporting of mood; • used convenience sampling; • reported anxiety as a continuous outcome and we were unable to obtain a categorical assessment from the author; and • measured anxiety by proxy.
Study identification and data extraction
Electronic searches in MEDLINE, EMBASE, PsycINFO, Allied and Complementary Medicine, CINAHL, and Proquest dissertation were conducted using the terms 'stroke' or 'cerebrovascular disorders' , or 'cerebrovascular accident' in combination with 'anxiety disorders' , or 'adjustment disorders' , or 'neurotic disorders' , or 'mental disorders' , or 'worry' , or 'fear' . The search terms were combined with the 'explode' feature and no language or date restrictions were put in place (see Appendix 1 for detailed search strategy). One investigator (ACB) conducted the initial search from database inception to March, 2010 and updated it up to March, 2011. Reference lists from included studies were checked, and study authors were contacted for additional data where necessary.
One reviewer (ACB) screened and identified studies against the selection criteria. A second reviewer (PK) conducted a random check of approximately 10% of titles and abstracts to check reliability of initial screening. Independent data extraction by two reviewers (ACB and PK) was performed for all eligible studies.
Quality of evidence
Information about study design, setting, and patient characteristics was extracted. Study quality was assessed using a modified version of the tool for systematic reviews of observational studies (QATSO) (20) , and each study was evaluated based on the method of recruitment into study, instrument used to measure anxiety, proportion of eligible patients who participated, proportion lost to follow-up (if applicable), and adequacy of descriptive details about the study populations. At a minimum, it was expected that age and gender would be reported.
Data synthesis
Studies were grouped into four categories based on method of case ascertainment. Population-based studies, which recruited all new stroke patients from a particular geographical area over a given period of time. These are regarded as the least biased method to identify cases in cohort studies. Hospitaland rehabilitation-based studies recruited inpatients, or those attending rehabilitation facilities. Lastly, community-based studies recruited patients not in hospital or rehabilitation facilities with no attempt to include all stroke cases in the geographic area (e.g. only patients from select general practices were included). Studies were also stratified by three time periods: the 'acute phase' (defined as less than onemonth poststroke), 'mid-term phase' (one-to five-months poststroke), and 'long-term phase' (six or more months poststroke).
Several meta-analyses were conducted. Studies using the DSM-III (21) were excluded from the pooled result as this classification system adheres to a strict hierarchical rule no longer used in practice, whereby anxiety is not diagnosed in the presence of depression. For studies that used rating scales, whatever threshold score for 'caseness' that had been selected by the primary researchers was accepted. In studies that measured anxiety over more than one time-point, the earliest measurement from each study was used in the meta-analysis for calculating overall prevalence rates. This was considered to be the most robust estimate, with the most complete follow-up data. Other meta-analyses stratified findings by source of study population (population; hospital, rehabilitation, or community) and time-period poststroke and used the same inclusion criteria described above. Data were summarized using the random effects model that takes into account the heterogeneity within and between studies. Chi-square was used to test for subgroup differences, and heterogeneity among the studies was assessed using the I 2 statistic. Heterogeneity is considered substantial if the I 2 statistic is greater than 50% (22) . Analysis was carried out using Review Manager 5·1 (Cochrane Collaboration, 2011).
Results
The search up to March 2010 produced 21 432 references, of which 50 publications (from 41 studies) met the inclusion criteria. Ten studies that could have potentially contributed to the review findings were excluded as authors were unavailable to provide necessary information. Reasons for exclusion were: reporting anxiety as a continuous outcome (23) (24) (25) (26) , using a rating scale that measured anxiety but not reporting anxiety findings (27) (28) (29) (30) , reporting only patients with comorbid anxiety and depression (31) , reporting only correlations between anxiety and another variable (32) , and an unpublished thesis that was not accessible (33) . An updated search run in March 2011 found three additional studies, giving a total of 44 studies included in this review.
Study characteristics
Five studies were population based and included 1054 stroke survivors from a base population of 1 199 782 (10, (34) (35) (36) (37) (38) (39) . Three studies were limited to those with first-ever stroke (10, 35, 37) , one excluded those with subarachnoid hemorrhage (36) , and none assessed anxiety in people with major cognitive impairment, dementia, or communication difficulties. Anxiety was assessed one-month to five-years poststroke, and 60-100% of eligible patients participated. The mean age of participants ranged from 66 to 71 years, with males representing 51-64% of the sample ( Table 1) . All studies were based on assessments from patients enrolled in a local stroke registry system.
There were 20 hospital-based (2,40-57,59) and 14 rehabilitation-based studies (60-74) that included 2163 and 2200 patients, respectively, all with variable inclusion criteria (Table 1) . Additionally, there were five community-based studies (75) (76) (77) (78) (79) including 343 patients (Table 1) . One study (79) accounted for 33% of the stroke participants. Among these three study types, participation rates ranged from 31% to 92%, and eight studies (43, 44, 46, 48, 58, 59, 63, 77) failed to provide information about the number of eligible stroke patients. Mean age ranged from 51 to 76 years with males comprising 45-72% of the study population (Table 1) .
Measurement and assessment of anxiety
Clinical diagnoses of anxiety disorders were made in eight studies in accordance with different versions of the DSM. The DSM-III (80) was used in three studies (10, 39, 49) , and three studies (34, 40, 73) used the DSM-III-R (21) . The Oxfordshire Community Stroke Project used the DSM-III-R for its longterm follow-up so it is counted in the DSM-III and DSM-III-R category. Another three studies (45, 53, 55) used the DSM-IV (6) . Eight different standardized scales were used to identify anxiety symptoms ( Table 2) . One study used a single question measure (70) , and another used a series of five researcherdeveloped questions to identify anxiety (75) .
Anxiety prevalence
Prevalence of anxiety disorders was 18% [95% confidence interval (CI) 8-29%, (I 2 = 97%, P < 0·001)] ( Fig. 1 ). Although the Perth Community Stroke Study (PCSS) used the DSM-III, it did not apply the hierarchical diagnostic rule, so it has been included in the meta-analysis. One study (73) with an unusually low prevalence estimate contributed all of the heterogeneity of the I 2 statistic. The prevalence of anxiety disorders excluding this study is 20% [95% CI 18-23%, (I 2 = 0%, P = 0·65)]. Three studies (34, 39, 53) that measured different anxiety types found that phobic disorders and GAD were the most common. One study that looked exclusively at GAD differentiated between primary GAD and GAD due to stroke (45) . It found that just over half of the anxiety cases received a primary diagnosis.
The overall frequency of anxiety 'caseness' when assessed by rating scale was 25% [95% CI 21-28%, (I 2 = 90%, P < 0·001)] ( Fig. 1 ). The HADS-A was the most commonly used rating scale ( Table 2 ). The majority of these studies used a HADS-A cutoff of 8/9 or 10/11 to define 'possible' or 'probable' anxiety. Studies using lower cutoffs on the HADS-A reported higher prevalence rates relative to those using the 'probable' threshold [(28%, 95% CI 21-35) vs. (18%, 95% CI 13-23%), I 2 = 79%, P = 0·03]. Assessment of the funnel plot ( Fig. 2 ) revealed more asymmetry among studies with lower cutoff scores relative to those using the 'probable' threshold, indicating possible publication bias in favor of studies with higher prevalence estimates. Post hoc analysis found no significant difference between studies that only included first-ever stroke compared with those with recurrent stroke (21% vs. 25%, respectively). the remaining stratified meta-analyses. There was a nonsignificant increase in the prevalence of anxiety over time.
Overall frequency was 20% [95% CI 13-26% (I 2 = 96%, P < 0·001)] in the acute phase; 23% [95% CI 19%-27% (I 2 = 84%, P < 0·001)] 1-5 months poststroke; and 24% [95% CI 19-29% (I 2 = 89%, P < 0·001)] six-months or more poststroke. Anxiety prevalence was significantly lower in the acute phase rehabilitation-based studies relative to the other stratified subgroups, 13% [95% CI 4-21%, I 2 = 97%]. Overall, the pooled population-based estimate (25%) was not significantly lower than those observed in hospital, rehabilitation, or community-based studies (25% vs. 21% vs. 22%, respectively). Three studies examined the time course of anxiety within individual stroke patients. The Collaborative Evaluation of Rehabilitation in Stroke across Europe study (64) found that 40% of patients with anxiety two-months after stroke remained anxious four-months later, and 7-11% of patients not anxious at two-months became so two to four-months later. The population-based PCSS (39) found that 16% of patients with anxiety disorder at four-months poststroke remained anxious eight-months later. A similar trend was observed in a small study by Astrom (40) , who reported that after three-years poststroke, 62% of patients with early onset GAD had not recovered; however, the small sample size from this last study mean results should be interpreted with caution.
Three studies (39, 45, 72) reported prestroke mood disorders and found that approximately one-third of patients with poststroke anxiety had a history of prestroke mood or anxiety disorder. Ten studies reported comorbidity of anxiety and depression (2, 39, 40, 42, 45, 53, 55, 60, 61, 71) and found that 17-80% of those with anxiety also had depression. No study reported whether stroke patients received any form of treatment for their anxiety. Additionally, two population-based studies with community-matched controls found no difference in anxiety prevalence rates between stroke and nonstroke patients (10, 39) . 
Clinical correlates
Investigating anxiety was rarely a primary aim of the studies included in the review. As such, factors that might be associated with anxiety were inconsistently reported. The variables correlated with anxiety and described in this section are those that were reported in five or more studies. There was a positive association between depression and anxiety in all six studies (45, 51, 55, 62, 68, 77) where it was assessed. Additionally, four of five studies (2, 48, 52, 68, 75) found a negative correlation with quality of life. Findings were mixed for activities of daily living with three studies (40, 42, 45) reporting a significant negative correlation and four studies (41, 42, 47, 54) finding no association with anxiety. No association was observed with age in six of eight studies (40, 42, 45, 46, 52, 53, 60, 62) ; gender in five of seven studies (40, 45, 46, 53, 55, 60, 62) ; or lesion location in five of six studies (34, 40, 42, 45, 60, 66) . It is likely that the probability of having anxiety after stroke is increased by having it before the stroke, but this relationship was not reported in enough studies to make an assessment.
Quality of evidence
Method of recruitment into studies was variable. The majority used consecutive recruitment and prevalence did not differ from studies that used a comprehensive registry. However, two studies that used random selection and one patient audit reported higher rates. There was also variability in prevalence estimates based on the rating scales used. As many of them were used in only one study, it is unclear whether this variability is due to the scale itself or some other underlying characteristic of the study population. The proportion of the eligible population participating in the study was associated with prevalence. It was lowest in studies whereby 60% or more of eligible individuals participated in the study (21%). Higher prevalence was observed in studies with less than 60% of eligible individuals included (25%) and was even higher for studies whereby the proportion participating was unclear (32%). None of the studies with longitudinal follow-up lost more than 50% of their sample at the subsequent time-point, and the majority of studies provided a sufficient level of detail to characterize the study population (Table 1 ).
Discussion
To our knowledge, this is the first published systematic review of anxiety prevalence after stroke. Anxiety disorders diagnosed by interview and anxiety symptoms assessed by rating scale occurred in approximately 20-25% of patients at any time after stroke. Phobic disorders and GAD were the most common types; however, this is based on findings from only three studies. The HADS was the most used rating scale. Sensitivity for detecting anxiety disorders using the HADS-A in stroke patients using the 'probable' cutoff score ranges between 0·35 and 0·52 (89, 90) and is only marginally better when using the 'possible case' threshold. As a result, the overall prevalence of anxiety 'caseness' has likely been underestimated. A recent validation study of the HADS-A in stroke patients found a score of 4 or 5 was the optimal cutoff when screening for anxiety (90) . At this level, the suggested requirements for psychological screening tools in stroke to have a sensitivity of >0·8 and specificity of >0·6 (91) are best met. Anxiety prevalence appears to increase somewhat over time; however, the increase is not statistically significant. It is possible that the lack of significance could be due to the stratified time periods chosen a priori; however, post hoc analysis selecting different time-points did not show a significant increase over time. With the exception of rates being lower in rehabilitation studies during the acute phase post stroke, no significant difference was observed based on the setting from which participants were recruited (e.g. population vs. hospital). A hypothesis is that the lower rate observed in the acute rehabilitation studies could be due to the structured supportive environment, or the notion that patients deemed appropriate for rehabilitation may be less disabled and as such less likely to be anxious. Given that anxiety prevalence beyond the acute phase is the same among rehabilitation patients as in other groups of patients, it is perhaps indicative of a negative shift in these patients' perception of their rehabilitation potential and chances of returning to their prestroke functional level. Furthermore, there is insufficient information to determine whether the anxiety reported was a consequence of stroke, as the majority of studies only made cross-sectional assessments and did not consider the presence of pre-stroke anxiety levels. Also, other factors that could impact on the validity of prevalence estimates such as medication use, the presence of cognitive or communication impairment, or previously having an anxiety disorder were not investigated. Despite having stratified our analyses by study population and timing, there was significant heterogeneity in the pooled estimates that impacts on the generalizability and interpretation of findings. Few studies differentiated between 'first-ever anxiety' and 'current anxiety' , making it impossible to determine whether the differences in estimates represent genuine discrepancies or were due to measurement error or methodological differences. Second, the variation in stroke subtypes, stroke severity, and inconsistency of diagnostic tools and rating scales likely contributed to the heterogeneity of the pooled estimate. The review relied on studies being cataloged in major search databases, and there was some evidence of potential publication bias. Additionally, some studies were not included in the review as their data were unavailable, and the influence this would have on the overall findings is unknown. With the exception of the HADS and the Beck Anxiety Inventory, the other scales used in these studies have not been validated in stroke populations, so their sensitivity and specificity are uncertain. The HADS was the most used rating scale; however, as it focuses on psychic symptoms, anxiety-related physical symptoms not attributed to stroke have not been taken into account.
Conclusion
This review shows that while there has been a large number of studies investigating and reporting on the frequency of anxiety after stroke, there is scant information about timing of onset, risk factors, and outcomes. There also remains a lack of clarity about potential management strategies. A recent systematic review of interventions used to treat anxiety after stroke found limited evidence for use of pharmaceutical drugs (92); however, other forms of treatment may be more suitable. For example, guided self-help, applied relaxation, and cognitive behavioral therapy have all been shown to be effective in the general adult population (93) . There is also a need to develop mood assessment tools appropriate for stroke patients with aphasia, severe communication problems, or neurological deficits as these individuals are generally excluded from research. To date, a visual analog mood scale found to be adequate in identifying depression poststroke has proved insufficient in the assessment of anxiety (91) .
Most studies tend to examine the phenomena of anxiety and depression in isolation. However, the pervasive use of mood scales such as the HADS could facilitate an evaluation of the impact on patients of anxiety in addition to depression. There may also be differential outcomes for those with anxiety only, depression only, and comorbidity; however, the design of most studies does not allow for any conclusion on this issue. Additionally, given the variability in cutoff scores used in research studies, clear guidance on the appropriate point to screen for anxiety is needed, as this would reduce, at least marginally, the heterogeneity among future studies and provide more clarity to clinical decisions about treatment. Recent large-scale surveys have reported dissatisfaction with the provision of psychological services after stroke (94) . The high prevalence of anxiety in combination with a lack of available support and treatment likely contribute to this finding. Given the pervasiveness of anxiety after stroke, an understanding of its impact on the patient and economic burden is warranted. 19 . (autonomic adj2 (arousal* or symptom*)).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier] 20. (hyperventilation adj2 (symptom* or syndrom*)).mp.
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